HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Inclusion Criteria:

1. Able to understand and voluntarily sign an informed consent form (ICF).

2. Adult aged ≥ 18 years at the time of informed consent (or other age required bylocal regulations).

3. Confirmed diagnosis of any of the following solid tumor:

4. Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma;

5. Hepatocellular carcinoma;

6. Lung squamous cell carcinoma;

7. Synovial sarcoma;

8. Triple-negative breast cancer;

9. Esophageal squamous cell carcinoma;

10. Cervical cancer;

11. Ovarian cancer

12. Patient who received standard curative or palliative therapy including but notlimited to any targeted therapy based on mutation status for their cancer, orpatient with advanced solid tumors for which there is no accepted therapy, standardtherapies are no longer effective, or the patient refuses additional standardtherapy.

13. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.

14. Body weight ≥ 50 Kg.

15. Life expectancy of ≥ 6 months.

16. Patient who agrees to provide the tumor sample for NY-ESO-1 IHC staining, fromeither fresh or archival tissue

Exclusion Criteria:

1. Known primary immunodeficiency (such as Severe Combined Immunodeficiency Disease orAIDS).

2. Uncontrolled intercurrent illness which is not suitable for enrollment at thediscretion of the investigator, including, but not limited to, ongoing or activeinfection, symptomatic congestive heart failure, unstable angina pectoris, unstablecardiac arrhythmia, psychiatric illness, or social situations that would limitcompliance with study requirements.

3. Currently confirmed diagnosis of at least 2 active cancers; patient who was cured ofthe other cancer [disease free period > 6 months] and currently has only oneresearch targeted tumor can be enrolled.

4. Untreated or symptomatic brain metastasis.

5. History of organ transplantation or allogeneic stem cell transplantation.

6. Other conditions (e.g. previous use of any cell therapy) which are not suitable forenrollment at the discretion of the investigator.